Methylphenidate for gait impairment in Parkinson disease
A randomized clinical trial
Citation Manager Formats
Make Comment
See Comments
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
Background: There is a paucity of therapies for gait impairment in Parkinson disease (PD). Open-label studies have suggested improved gait after treatment with methylphenidate (MPD).
Objective: To evaluate the efficacy of MPD for the treatment of gait impairment in PD.
Methods: Twenty-seven subjects with PD and moderate gait impairment were screened for this 6-month placebo-controlled, double-blind study. Subjects were randomly assigned to MPD (maximum, up to 80 mg/day) or placebo for 12 weeks and crossed over after a 3-week washout. The primary outcome measure was change in a gait composite score (stride length + velocity) between groups at 4 and 12 weeks. Secondary outcome measures included changes in motor function, as measured by the Unified Parkinson's Disease Rating Scale (UPDRS), Freezing of Gait Questionnaire (FOGQ), number of gait-diary freezing episodes, and measures of depression, sleepiness, and quality of life. Three-factor repeated-measures analysis of variance was used to measure changes between groups.
Results: Twenty-three eligible subjects with PD were randomized and 17 completed the trial. There was no change in the gait composite score or treatment or time effect for any of the variables. Treatment effect was not modified by state or study visit. Although there was a trend for reduced frequency of freezing and shuffling per diary, the FOGQ and UPDRS scores worsened in the MPD group compared to placebo. There was a marginal improvement in some measures of depression.
Conclusions: MPD did not improve gait and tended to worsen measures of motor function, sleepiness, and quality of life.
Classification of evidence: This study provides Class III evidence for the lack of benefit of MPD on PD-associated gait impairment. Clinical trial registration: NCT00526630.
Footnotes
-
Study funding: Supported by the Michael J Fox Foundation.
-
Supplemental data at www.neurology.org
-
- ESS
- Epworth Sleepiness Scale
- FOGQ
- Freezing of Gait Questionnaire
- GDS
- Geriatric Depression Scale
- MADRS
- Montgomery-Åsberg Depression Rating Scale
- MPD
- methylphenidate
- PD
- Parkinson disease
- STN DBS
- subthalamic deep brain stimulation
- UPDRS
- Unified Parkinson's Disease Rating Scale
- Received August 3, 2010.
- Accepted December 22, 2010.
- Copyright © 2011 by AAN Enterprises, Inc.
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
- Methylphenidate for gait impairment in Parkinson disease: A randomized clinical trial
- Paul B. Foley, Neuroscience Historian, Neuroscience Research Australiap.foley@neura.edu.au
Submitted August 23, 2011 - Reply from the authors
- Alberto J. Espay, Assistant Professor of Neurology, 260 Stetson St., Suite 2300 University of Cincinnati, P.O. Box 670525), Cincinnati, OH 45267-0525alberto.espay@uc.edu
- Brian N. Maddux, Fredy J. Revilla, Andrew P. Duker, John T. Slevin
Submitted August 23, 2011
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Dennis Bourdette and Dr. Lindsey Wooliscroft
► Watch
Topics Discussed
Alert Me
Recommended articles
-
Article
Association of metabolic syndrome and change in Unified Parkinson's Disease Rating Scale scoresMaureen Leehey, Sheng Luo, Saloni Sharma et al.Neurology, September 29, 2017 -
Article
Changes in insomnia subtypes in early Parkinson diseaseLena K. Tholfsen, Jan P. Larsen, Jörn Schulz et al.Neurology, December 16, 2016 -
Articles
Effects of subthalamic nucleus stimulation and levodopa on freezing of gait in Parkinson diseaseM. U. Ferraye, B. Debû, V. Fraix et al.Neurology, April 14, 2008 -
Views and Reviews
A meta-regression of the long-term effects of deep brain stimulation on balance and gait in PDR.J. St. George, J.G. Nutt, K.J. Burchiel et al.Neurology, October 04, 2010